Shilpa Medicare Share Price

Shilpa Medicare

CMP as on 24-May-22 15:46

₹ 452.95
43.00 10.49%

Open

₹ 448.00

Turnover (lac)

₹ 22,428

Prev. Close

₹ 409.95

Day's Vol (shares)

₹ 49,51,440

Day's Range (₹)

₹ 435.15
₹ 471.00

CMP as on24-May-22 15:43

₹ 453.25
42.95 10.47%

Open

₹ 439.00

Turnover (lac)

₹ 71

Prev. Close

₹ 410.30

Day's Vol (shares)

₹ 1,49,062

Day's Range

₹ 435.25
₹ 470.00

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 16-May-2022 - -
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2022 inter alia to consider and approve 1. Approval of the Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and the financial year ended 31 March 2022 2. Recommendation of Dividend if any for the financial Year ended 31 March 2022 Shilpa Medicare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 23, 2022, inter alia, has considered and approved the following: Recommendation of Dividend: Payment of dividend of Rs. 1.10/- (110%) per equity share of face value of Rs. 1/- each for the financial year 2021-2022, subject to approval of members in the ensuing Annual General Meeting. (As Per BSE Announcement dated on 23.05.2022)
Board Meeting - 02-Feb-2022 - -
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2022 inter alia to consider and approve Approval of the un-audited Standalone and Consolidated Financial Results of the Company for the Third Quarter ended 31 December 2021. Approval of Unaudited Standalone and Consolidated Financial Results of the Company for the Third Quarter ended 31 December 2021. (As per BSE Announcement Dated on 08/02/2022) With reference to the captioned subject, we hereby wish to inform that the Board of Directors at their meeting held on 08 February 2022, inter alia discussed and took note the following; Resignation of Mr. Naresh Patwari as a Non-executive Director of the Company with effect from 02 February 2022. Resignation of Mr. Piyush Goenka as an Independent Director of the Company with effect from 07 February 2022. Request you to take the same on record. (As per BSE Announcement Dated on 09/02/2022)
Board Meeting - 12-Nov-2021 - -
Intimation of allotment of 52,75,000 (Fifty Two Lakh Seventy Five Thousand) Equity Shares of the Company having face value of Re.1/- (Rupee One) each at a price of Rs. 564/- (Rupees Five Hundred and Sixty Four) per share on preferential basis.
Board Meeting - 25-Oct-2021 - -
Quarterly Results This is to clarify that the Board Meeting of Shilpa Medicare Limited to discuss and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the Second Quarter ended 30th September, 2021 will be held on Friday, 29th October, 2021. Kindly take the same on record. (As Per BSE Announcement dated on 24.10.2021) Approval of Unaudited Standalone and Consolidated Financial Results of the Company for the Second Quarter AND Half Year ended 30 September 2021. (As Per BSE Announcement dated on 29.10.2021)
Board Meeting - 11-Oct-2021 - -
Preferential Issue of shares & Issue Of Warrants Inter alia to consider the issue of Equity Shares and/or convertible securities including warrants on Preferential basis under SEBI (ICDR) Regulations, 2018, including determination of issue price as may be permitted under applicable laws, subject to such regulatory / statutory approvals as may be required including approval of shareholders of the Company. We inform you that the Board of Directors (Board) approved, at their meeting held today i.e on 14th October, 2021, subject to the approval of members, for raising of funds up to Rs.297.51 Crores by issuing equity shares on preferential basis to various investors, the brief details of which, according to SEBI Circular CIR/CFD/CMD/4/2015 dated September, 09, 2015 (As per BSE Announcement Dated on 14/10/2021)
Board Meeting - 07-Aug-2021 - -
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2021 inter alia to consider and approve With reference to the subject cited above we wish to inform you that a meeting of the Board of Directors of Shilpa Medicare Limited will be held on Saturday the 14th day of August 2021 to inter alia transact the following items of business: Approval of the Audited Standalone and Consolidated Financial Results of the Company for the First Quarter ended 30th June 2021. This is to inform you that with reference to the captioned subject the Board of Directors of Shilpa Medicare Limited at their meeting held today i.e., Saturday. 14 August 2021 inter alia resolved the following. Approval of Un-Audited Standalone and Consolidated Financial Results for the Quarter ended 30 June 2021. Please find attached herewith outcome with quarterly results. This is to inform you that with reference to the captioned subject the Board of Directors of Shilpa Medicare Limited at their meeting held today i.e., Saturday. 14 August 2021 inter alia resolved the following. Approval of Un-Audited Standalone and Consolidated Financial Results for the Quarter ended 30 June 2021. The Board meeting commenced at 12:15 PM and concluded at 03:15 PM (As per BSE Announcement Dated on 14/08/2021)
Board Meeting - 12-Jul-2021 - -
This is to intimate that the Board of Directors at its meeting held today, approved the transfer of API Business of the Company consisting of Unit-1 and Unit-2 situated at Raichur, Karnataka by way of slump sale to a wholly Owned Subsidiary of the Company (to be incorporated) subject to the approval of Shareholders. The detailed disclosure as required under Regulation 30 of SEBI (LODR) Regulations, 2015 is attached hereto as Annexure
Board Meeting - 24-May-2021 - -
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/05/2021 ,inter alia, to consider and approve Approval of the Audited Standalone and Consolidated Financial Results of the Company for the Fourth Quarter and the Financial Year ended 31st March, 2021. We inform you that the Board may inter-alia, consider the proposal of recommendation of dividend, if any, for the financial year 2020-21 at their meeting to be held on Monday, the 31st Day of May, 2021. (AS Per BSE Announcement Dated on 25.05.2021) With reference to the captioned subject please be noted that the board of directors at their meeting held today 31.05.2021, to inter alia considered and approved the following. 1. Audited Standalone and Consolidated Financial Statements for the Financial Year ended 31st March, 2021. 2. Auditors Report for the Financial Year ended 31st March, 2021. 3. To recommend the Dividend @ 110% (i.e. Rs.1.10 per every equity share of face value of Rs.1) for the Financial Year 2020-21 subject to the approval of shareholders at the ensuing Annual General Meeting. 4. Appointment of Mr. Alpesh Dalal as Chief Financial Officer of the Company. Brief profile is enclosed as an annexure The board Meeting Started at 11:30 am and Concluded at 15:10 PM. With reference to the captioned subject please be noted that the board of directors at their meeting held today 31.05.2021, to inter alia considered and approved the following. 1. Audited Standalone and Consolidated Financial Statements for the Financial Year ended 31st March, 2021. 2. Auditors Report for the Financial Year ended 31st March, 2021. 3. To recommend the Dividend @ 110% (i.e. Rs.1.10 per every equity share of face value of Rs.1) for the Financial Year 2020-21 subject to the approval of shareholders at the ensuing Annual General Meeting. 4. Appointment of Mr. Alpesh Dalal as Chief Financial Officer of the Company. Brief profile is enclosed as an annexure The board Meeting Started at 11:30 am and Concluded at 15:10 PM. (As Per BSE Announcement Dated on 5/31/2021 3:27:52 PM APPOINTMENT OF MR. ALPESH DALAL AS CHIEF FINANCIAL OFFICE OF THE COMPANY (AS Per BSE Announcement Dated on 01.06.2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity